Diagnostics and Therapeutics for HIV: Global Markets

Nov 2018| PHM058C| BCC Publishing

Report Highlights

The global HIV therapeutics market should reach $27.1 billion by 2023 from $22.0 billion in 2018 at a compound annual growth rate (CAGR) of 4.3% for the period of 2018 to 2023.

Report Includes

  • 37 data tables and 49 additional tables
  • Industry analysis of diagnostics and therapeutics for the HIV disease, and its global markets
  • Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
  • Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
  • Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
  • Examination of cost implications for treatments across a range of countries
  • A look at ongoing research and the future direction of the market
  • Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific

Report Scope

This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Diagnostics and Therapeutics for HIV: Global Markets184 $2,750 Free
Chapter- 1: Introduction7Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Overview10$153Free
Chapter- 4: Global Industry Trends7$107Free
Chapter- 5: Global HIV Therapeutics Market45$688Free
Chapter- 6: HIV Therapeutics Market by ARV Drug Categories23$351Free
Chapter- 7: Leading Drugs in the HIV Therapeutics Market9$138Free
Chapter- 8: HIV Diagnostics Market18$275Free
Chapter- 9: Pipeline Analysis9$138Free
Chapter- 10: Regulatory and Reimbursement Structure11$168Free
Chapter- 11: Competitive Landscape and Key Developments8$122Free
Chapter- 12: Company Profiles31$474Free
Chapter- 13: Appendix: Abbreviations and Glossary4$61Free
Published - Apr-2014| Analyst - Kritika Chaudhari| Code - PHM058B

Report Highlights

The global market for HIV therapeutics is expected to grow to $18.2 billion in 2013 and $19.6 in 2018, with a compound annual growth rate (CAGR) of 1.5%.

Report Includes

  • An overview of the global market for HIV therapeutics and diagnostics
  • Analyses of global market trends, with data from 2013, and estimates and projections of CAGRs through 2018.
  • Discussion of improvements in advanced treatments and diagnostic methods.
  • Examination of cost implications for treatments accross a wide range of countries
  • A look at ongoing research and the future direction of the market.

Published - Mar-2011| Analyst - Paul Evers| Code - PHM058A

Report Highlights

The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast period to reach $14.1 billion in 2016.

Diagnostics and Therapeutics for HIV: Global Markets

Single User License: $2750

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report